Research issues involving hiv-associated tuberculosis in resource-poor countries

JAMA

Volumn 276, Issue 18, 1996, Pages 1502-1507

  De Cock, Kevin M ^a   Binkin, Nancy J ^b   Zuber, Patrick L F ^b   Tappero, Jordan W ^b   Castro, Kenneth G ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BCG VACCINATION; DEVELOPING COUNTRY; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LUNG TUBERCULOSIS; PRIORITY JOURNAL; RESOURCE ALLOCATION; TUBERCULOSIS CONTROL;

EID: 0029957260     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.18.1502     Document Type: Article

References (81)

1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220-226.
2. Centers for Disease Control and Prevention. Estimates of future global tuberculosis morbidity and mortality. MMWR Morb Mortal Wkly Rep. 1993; 42:961-964.
3. Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Tuber Lung Dis. In press.
4. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis. 1990;65:6-24.
5. The World Bank. Investing in Health: World Development Report 1993. New York, NY: Oxford University Press; 1993.
6. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva, Switzerland: World Health Organization; 1993.
7. Enarson DA, Rieder HL, Arnadottir T. Tuberculosis Guide for Low Income Countries. 3rd ed. Paris, France: International Union Against Tuberculosis and Lung Disease; 1994.
8. Cantwell MF, Binkin NJ. Tuberculosis and HIV in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis. 1996;77:220-225.
9. De Cock KM, Gnaore E, Adjorlolo G, et al. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. BMJ. 1991;302: 496-499.
10. Elliott AM, Namaambo K, Allen BW, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis. 1993;74:191-194.
11. Abouya L, Coulibaly IM, Coulibaly D, et al. Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2 infected patients in Abidjan, Cote d'Ivoire. Tuber Lung Dis. 1995;76:436-440.
12. Lucas SB, Hounnou A, Peacock C, Beaumel A, Kadio A, De Cock KM. Nocardiosis mimicking tuberculosis in HIV-positive patients: an autopsy study in West Africa. Tuber Lung Dis. 1994;75: 301-307.
13. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS. 1993;7:1569-1579.
14. De Cock KM, Wilkinson D. Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. Lancet. 1995;346:675-677.
15. Rickman TW, Moyer NP. Increased sensitivity of acid-fast smears. J Clin Microbiol. 1980;11:618-620.
16. Gebre N, Karisson U, Jönsson G, et al. Improved microscopical diagnosis of pulmonary tuberculosis in developing countries. Trans R Soc Trop Med Hyg. 1995;89:191-193.
17. Saceanu CA, Pfeiffer NC, McLean T. Evaluation of sputum smears concentrated by cytocentrifugation for detection of acid-fast bacilli. J Clin Microbiol. 1993;31:2371-2374.
18. Grosset J, Mouton Y. Is PCR a useful tool for the diagnosis of tuberculosis in 1995? Tuber Lung Dis. 1995;76:183-184.
19. Jacobs WR, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science. 1993;260:819-822.
20. Rieder HL. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis. 1995;76:114-121.
21. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis. 1992;73:311-321.
22. Smith PJ, Binkin N, Castro KG. Design and analysis of annual risk of infection surveys. In: Proceedings and abstracts of the Conference on Global Lung Health and the 1995 Annual Meeting of the IUATLD/UICTMR; September 9-12, 1995; Paris, France. Abstract 347-PA10.
23. Centers for Disease Control and Prevention. National action plan to combat multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 1992; 41:1-48.
24. Braun MM, Kilburn JO, Smithwick R, et al. HIV infection and primary resistance to antituberculous drugs in Abidjan, Ivory Coast. AIDS. 1992; 6:1327-1330.
25. Githui W, Nunn PP, Juma E, et al. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Tuber Lung Dis. 1992;73:203-209.
26. Vareldzis BP, Grosset J, deKantor J, et al. Laboratory Evaluation of Drug Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 1993. World Health Organization publication WHO/ TB/93.171.
27. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment for tuberculosis: we can't afford not to try it. N Engl J Med. 1993;328:576-578.
28. Weis SE, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-1184.
29. Nunn P, Felten M. Surveillance of resistance to antituberculosis drugs in developing countries. Tuber Lung Dis. 1994;75:163-167.
30. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and other conventional epidemiologic methods. N Engl J Med. 1994;330: 1710-1716.
31. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med. 1994;330:1703-1709.
32. Sassan-Morokro M, De Cock KM, Ackah A, et al. Tuberculosis and HIV infection in children in Abidjan, Cote d'Ivoire, West Africa. Trans R Soc Trop Med Hyg. 1994;88:178-181.
33. Chintu C, Bhat G, Luo C, et al. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Pediatr Infect Dis J. 1993;12:499-504.
34. Lucas SB, Peacock CS, Hounnou A, et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. BMJ. 1996;312:335-338.
35. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet. 1989;2:1502-1504.
36. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep. 1994;43(RR-13):1-132.
37. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
38. Small PM, Shafer RW. Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328:1137-1144.
39. IUATLD/WHO. Control of tuberculosis in health care settings. Tuber Lung Dis. 1994;75:94-95.
40. Di Perri G, Cadeo GP, Castelli F, et al. Transmission of HIV-associated tuberculosis to health care workers. Infect Control Hosp Epidemiol. 1993; 14:67-72.
41. Castro KG, Dooley SW. Mycobacterium tuberculosis transmission in health care settings: is it influenced by coinfection with human immunodeficiency virus? Infect Control Hosp Epidemiol. 1993; 14:65-66.
42. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991;377:627-630.
43. Pozniak AL, MacLeod GA, Mahari M, Legg W, Weinberg J. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. AIDS. 1992;6:809-814.
44. Colebunders RL, Ryder RW, Nzilambi N, et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis. 1989;139:1083-1085.
45. Perriens JH, Colebunders EL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis. 1991;144:750-755.
46. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya Lancet. 1993;342:332-337.
47. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis. 1992;146:849-854.
48. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991; 324:289-294.
49. Kassim S, Sassan-Morokro M, Ackah A, et al. Two year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS. 1995;9:1185-1191.
50. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet. 1994;344:1323-1328.
51. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779-784.
52. Gangadharam PRJ. Chemotherapy of tuberculosis under program conditions. Tuber Lung Dis. 1994;75:241-244.
53. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis. 1991;144:745-749.
54. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet. 1995;345: 607-610.
55. Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311-1320.
56. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345:1545-1548.
57. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet. 1994;343:647-648.
58. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2,4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis. 1991;143: 700-706.
59. Stanford JL, Grange JM, Pozniak A. Is Africa lost? Lancet. 1991;338:557-558.
60. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 1995; 89:78-82.
61. Martin DJ, Sim JGM, Sole GJ, et al. CD4+ lymphocyte counts .in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:386-391.
62. Brindle RJ, Nunn PP, Batchelor BIF, et al. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS. 1993;7:1469-1474.
63. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d'Ivoire. AIDS. 1995;9:1251-1254.
64. Lange JMA. HIV-related morbidity and mortality in sub-Saharan Africa: opportunities for prevention. AIDS. 1993;7:1675-1676.
65. Fine PEM. Bacille Calmette-Guerin vaccines: a rough guide. Clin Infect Dis. 1995;20:11-14.
66. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346:1339-1345.
67. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 1994;271:698-702.
68. World Health Organization. Special Programme on AIDS and Expanded Programme on Immunization - joint statement: consultation on human immunodeficiency virus (HIV) and routine childhood immunization. Wkly Epidemiol Rec. 1987;62:297-309.
69. Lallemant-Le Coeur S, Lallemant M, Cheynier D, Nzingoula S, Drucker J, Larouze B. Bacillus Calmette-Guerin immunization in infants born to HIV-1 seropositive mothers. AIDS. 1991;5:195-199.
70. Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1993;12:993-997.
71. Braun MM, Cauthen G. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and bacillus Calmette-Guerin immunization. Pediatr Infect Dis J. 1992;11:220-227.
72. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
73. De Cock KM, Grant A, Porter JDH. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet. 1995;345:833-836.
74. O'Brien RJ, Perriens JH. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS. 1995;9:665-673.
75. Aisu T, Raviglione MC, Van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS. 1995;9:267-273.
76. Murray CJL, Kreuser J, Whang W. Cost-effectiveness analysis and policy choices: investing in health systems. Bull World Health Organ. 1994; 72:663-674.
77. De Cock KM. Screening for tuberculosis and HIV in resource-poor countries. Lancet. 1995;345: 873-874.
78. Barry M. Ethical considerations of human investigation in developing countries: the AIDS dilemma N Engl J Med. 1988;319:1083-1086.
79. De Cock KM, Ekpini E, Gnaore E, Kadio A, Gayle H. The public health implications of AIDS research in Africa. JAMA. 1994;272:481-486.
80. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995;333:229-233.
81. Wilkinson D, Davies GR, Connolly C. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am J Public Health. 1996;86:1094-1097.